Reduction in pediatric growth hormone deficiency and increase in central precocious puberty diagnoses during COVID 19 pandemics

Martina Peinkhofer1, Benedetta Bossini1, Arturo Penco1, Manuela Giangreco2, Maria Chiara Pellegrini2, Viviana Vidonis2, Giada Vittori2, Nicoletta Grassi2, Elena Faleschini2, Egidio Barbi1,2 and Gianluca Tornese2*

Abstract

Background: While several studies have been published so far on the effect of COVID-19 pandemic on health care for non-COVID-19 diseases, to date no study evaluated the impact of the COVID-19 pandemic on the entire field of pediatric endocrinology. This study aimed to evaluate differences in pediatric endocrine stimulation tests after the advent of COVID-19 pandemics.

Methods: Retrospective study with data collection for pediatric endocrine stimulation tests performed in 2019 and 2020 in a tertiary center.

Results: Overall, 251 tests were performed on 190 patients in 2020, compared to 278 tests on 206 patients in 2019 (−10% tests; −8% children evaluated). A significant reduction was found in tests to diagnose growth hormone deficiency (GHD) (−35%), while LHRH tests increased (+22%). A reduction of 30% in GHD diagnosis was observed. Central precocious puberty (CPP) diagnosis increased by 38% compared to 2019, mainly in females.

Conclusion: This study found a significant reduction of tests investigating GHD during COVID-19 pandemics. It also showed a clinically meaningful increase in cases of CPP in girls. These results suggest the need for families and pediatricians to monitor children’s growth during isolation and enlighten new perspectives towards conditions associated with lockdown restrictions as increased screen time, social isolation, and children’s anxiety as possible triggers of CPP.

Keywords: Stimulation test, Central precocious puberty, Growth hormone deficiency, COVID-19

Background

The two most frequent referral reasons in pediatric endocrinology are issues regarding growth and puberty, which constitutes almost half of the referrals for pediatric endocrinologists [1]. To detect growth hormone deficiency (GHD) or central precocious puberty (CPP), among other endocrine diseases, the determination of basal hormones is of limited diagnostic value, and stimulation tests – which require hospital admission – are needed. Although some cases of CPP could even be diagnosed by determining basal values of LH, FSH, and sexual hormones, stimulation tests are still extensively used and considered the gold standard in the diagnosis and help in diagnosing cases where basal values are not conclusive [2].

Due to the COVID-19 pandemic, from March 9th, Italy was placed under the first national generalized lockdown: people across the entire peninsula, with unprecedented measures, were ordered to stay at home, and travels were banned, excluding only those for “urgent, verifiable work situations and emergencies or health reasons.” To reduce pressure on hospitals and minimize the hazard of direct person-to-person exposure, non-urgent visits...
were reduced. Also, schools of all levels, from kindergarten to universities, were kept closed for physical attendance, while teaching was pursued by telematic means. All activities gradually resumed from May 4th to June 15th, 2020, and until October 26th, when Italian authorities introduced new restrictions nationwide until May 2021.

While several studies have been published so far on the effect of COVID-19 pandemic on health care for non-COVID-19 diseases, mainly in pediatric emergency departments, indicating a reduction in both urgent and non-urgent visits [3–11], to date, no study evaluated the impact of the COVID-19 pandemic on the entire field of pediatric endocrinology.

This study aimed to evaluate differences between 2019 and 2020 in pediatric endocrine stimulation tests performed in a tertiary hospital.

Material and methods

We conducted a retrospective study at the Institute for Maternal and Child Health IRCCS “Burlo Garofolo” in Trieste, Italy, a tertiary hospital and research institute that serves as a pediatric referral center for the province of Trieste and as a national reference hospital.

During COVID-19 pandemics, admissions for endocrine stimulation tests were among the procedures that were considered urgent and therefore not canceled. The available number of beds for investigations remained unchanged to 300 per year. All records of children and adolescents performing a stimulation test from January 1st to December 31st, 2019 [2] and from January 1st to December 31st, 2020, were reviewed. The “G2 clinico” platform (management system specialist activities) was employed to access all patients’ data. Information retrieved included age at presentation, gender, height SDS, BMI SDS, type and number of tests performed, reason(s) for referral, test results, and final diagnosis. Stimulation tests were performed and interpreted as previously described [2].

Ethical Committee approval was not requested since General Authorization to Process Personal Data for Scientific Research Purposes (Authorization no. 9/2014) declared that retrospective archive studies that use ID codes, preventing the data from being traced back directly to the data subject, do not need ethics approval [12]. Parents signed informed consent at the first visit, in which they agreed that “clinical data may be used for clinical research purposes, epidemiology, the study of pathologies and training, to improve knowledge, care, and prevention.”

Statistical analyses were mainly descriptive. Data are presented as frequencies and percentages or as median and interquartile ranges (IQRs) due to non-normal distribution. Fisher’s exact test was used to evaluate associations between two categorical variables, while the non-parametric Wilcoxon Mann-Whitney test was applied to assess the difference in the distribution of a continuous variable across the two groups of a categorical variable. A P-value < 0.05 was considered statistically significant. Analyses were performed with JMP™ software (version 16.1.0, SAS Institute Inc., Cary, NC, United States).

Results

Overall, while in 2019 278 tests were performed on 251 patients in 2019 (47% females) with a median age of 11.1 years (IQR 8.0;14.0), in 2020 251 tests were performed on 190 patients (66% females, \( p<0.05 \)) with a median age of 12.1 years (IQR 8.1;15.1); 59 individuals (29%) in 2019 and 48 individuals (25%) in 2020 performed more than 1 test.

The distribution of stimulation tests and pathological response is reported in Table 1. A significant difference among performed tests was found between 2019 and 2020 (\( p<0.01 \)): while in 2019 the most frequently performed test was Arginine Tolerance Test (ATT: \( n=95, 34\% \)), in 2020 it was Luteinizing Hormone Releasing Hormone (LHRH) Test (LHRHT: \( n=81, 33\% \)).

GHD tests

Among tests evaluating a suspected GHD (arginine [ATT], insulin [ITT], and clonidine [CTT] tolerance tests), a total reduction from 126 to 80 was detected (Table 1): 86 children were investigated for short stature in 2019 and 52 in 2020 (\( p<0.01 \)), and GHD was diagnosed in 26 children in 2019 and 18 in 2020 (\( p=0.02 \)) (Fig. 1). Median age at first stimulation test was 12.0 years (IQR 8.7;13.0) in 2019 and 12.5 years (IQR 9.0;13.5) in 2020 (\( p=0.24 \)). Overall, in 2020 there was a 40% reduction of patients evaluated for a suspected GHD with a decrease of 30% in diagnoses of GHD compared to 2019, while the rate of positive tests was similar in the 2 years (30% in 2019, 35% in 2020) (\( p=0.81 \)). No differences were found in height SDS at first stimulation test between 2019 (median – 2.20 [IQR -2.57;-1.79]) and 2020 (median – 2.17 [IQR -2.71;-1.46]) (\( p=0.91 \)).

LHRH tests

Details regarding LHRH tests are provided in Table 2. The median age at test was 7.8 years (IQR 7.1;8.5) for females and 9.0 years for males (IQR 8.8;9.6). An increase of tests for a suspect of CPP in 2020 (+13%) was associated with a rise in pubertal responses (+17%) compared to 2019. Considering tests performed for suspected CPP, the number of diagnoses in females was higher in 2020 than in 2019: 16 diagnoses in 2019 (42% of tests) vs. 26
diagnoses in 2020 (58% of tests) \(p=0.03\). No differences were found in age between the two years for females \(p=0.26\) and males \(p=0.74\).

There was not a significant difference in BMI SDS for children with a suspect of CPP between 2019 (median 0.45 [IQR -0.16;1.01]) and 2020 (median 0.45 [IQR

### Table 1 Distribution of endocrine stimulation test according to suspected diagnosis and pathological tests in 2019 and 2020 (\(^a\) ITT were performed to detect both GHD and CAI simultaneously)

| Suspected diagnosis | Stimulation test | N of performed tests | N of pathological tests | % of pathological tests | N of performed tests | N of pathological tests | % of pathological tests |
|---------------------|------------------|----------------------|-------------------------|------------------------|----------------------|-------------------------|------------------------|
| GHD                 | ATT              | 95                   | 39                      | 41%                    | 60                   | 25                      | 42%                    |
|                     | ATT + GHRHT      | 1                    | 1                       | 100%                   | 1                    | 1                       | 100%                   |
|                     | CTT              | 31                   | 25                      | 81%                    | 19                   | 16                      | 84%                    |
| NC-CAH              | SDST             | 52                   | 0                       | 0%                     | 56                   | 1                       | 2%                     |
| CPP                 | LHRT             | 48                   | 24                      | 50%                    | 54                   | 28                      | 52%                    |
| CAI                 | ITT\(^a\)        | 31                   | 5                       | 16%                    | 19                   | 4                       | 21%                    |
|                     | LDST             | 16                   | 1                       | 6%                     | 13                   | 1                       | 8%                     |
|                     | CRHT             | 1                    | 0                       | 0%                     | 1                    | 0                       | 0%                     |
| HH                  | LHRT             | 18                   | 5                       | 28%                    | 27                   | 1                       | 4%                     |
| AGHD                | ATT + GHRHT      | 17                   | 0                       | 0%                     | 15                   | 1                       | 7%                     |
| CH                  | TRHT             | 1                    | 1                       | 100%                   | 4                    | 2                       | 50%                    |

\(AGHD\) Adult Growth Hormone Deficiency, \(ATT\) Arginine Tolerance Test, \(ATT + GHRHT\) Arginine Tolerance Test + Growth Hormone Releasing Hormone Test, \(CAI\) Central Adrenal Insufficiency, \(CH\) Central Hypothyroidism, \(CPP\) Central Precocious Puberty, \(CRHT\) Corticotropin-Releasing Hormone Test, \(CTT\) Clonidine Tolerance Test, \(GHD\) Growth Hormone Deficiency, \(HH\) Hypogonadotropic Hypogonadism, \(ITT\) Insulin Tolerance Test, \(LDST\) Low-Dose Synacthen Test, \(LHRHT\) Luteinizing Hormone-Releasing Hormone Test, \(NC-CAH\) Non-Classical Congenital Adrenal Hyperplasia, \(OG\) OverGrowth, \(OGTT\) Oral Glucose Tolerance Test, \(SDST\) Standard-Dose Synacthen Test, \(TRHT\) Thyrotropin Releasing Hormone

---

**Fig. 1** Diagnostic process for children with suspected growth hormone deficiency (GHD) in 2019 and 2020

---

86 individuals with suspected GHD

1st stimulation test
(85 ATT; 1 ATT+GHRHT)

34 (40%)
1st pathologic test
(33 ATT; 1 ATT+GHRHT)

2nd stimulation test
(28 ITT; 8 ATT)

26 (76%)
2nd pathologic test
(22 ITT; 4 ITT)

26 GHD (30% on initial cohort)

52 normal test
(52 ATT)

8 normal test
(6 ITT; 2 ATT)

18 (80%)
2nd pathologic test
(16 ITT; 2 ITT)

18 GHD (35% on initial cohort)

---

52 individuals with suspected GHD

1st stimulation test
(51 ATT; 1 ITT)

20 (30%)
1st pathologic test
(20 ATT)

2nd stimulation test
(16 ITT; 4 ATT)

2 normal test
(2 ATT)

---

2 normal test
(2 ATT)
While no significant differences were found in BMI SDS between all children diagnosed with CPP in 2019 (median 0.46 [IQR 0.13;1.01]) and in 2020 (median 0.17 [−0.30;0.74]) (p = 0.15), females diagnosed with CPP in 2020 had a BMI SDS (median 0.11 [IQR -0.52;0.72]) significantly lower than those diagnosed in 2019 (median 0.93 [IQR 0.38;1.10]) (p = 0.01).

**Discussion**

In this retrospective study, we comprehensively analyzed differences in endocrine stimulation tests performed in a pediatric endocrinology outpatient department between 2019 and 2020 to detect any effect of COVID-19 pandemic restrictions.

Overall, we found a reduction of 10% in tests and 8% in children evaluated between 2019 and 2020, which was not related to hospital policies, since endocrine stimulation tests were considered urgent admissions during COVID-19 lockdown and the available number of beds for investigations remained unchanged. The most significant detected changes were a reduction in tests to diagnose GHD (−30% of patients diagnosed in 2020) and an increase in CPP diagnosis (+38%, mainly females).

Regarding the tests investigating GH secretion, we detected a striking reduction (−35%) in tests performed in 2020, compared to 2019. This was sharply in contrast with a steady increase in referrals for growth issues that we reported from 2014 to 2018 in a previous study [1], even though the criteria – according to the Italian Medicines Agency (AIFA) – to perform stimulation tests were the same (i.e., height ≤ −3 SD; or height ≤ −2 SD + growth velocity per year ≤ −1 DS for age and sex evaluated for at least 6 months or a reduction of height of 0.5 SD per year in children > 2 years of age; or height ≤ −1.5 SD compared to target height and growth velocity per year ≤ −2 SD or ≤ −1.5 SD for two consecutive years; or growth velocity per year ≤ −2 SD or ≤ −1.5 SD after two consecutive years, even without short stature and after exclusion of other causes of failure to thrive; or malformations/lesions of hypothalamus/pituitary demonstrated at brain MRI) [13]. Although this is the first study reporting a decrease of referrals for suspected GHD during 2020 lockdowns, our results align with previous reports addressing a delay of hospital care admissions and a reduction of 30–40% in visits during the COVID-19 pandemic [9, 10]. A possible explanation for the decrease in tests for suspected GHD is that well-child visits were canceled during the pandemics, removing a chance for family pediatricians to detect short stature and delayed growth. Moreover, families did not have the opportunity to compare their children with classmates (because of remote schooling and the absence of other social activities), missing possible deviations from the regular growth pattern to share with their family pediatricians. Although not considered in the present study, we have to contemplate that some families might have canceled their booked appointment because they feared going to the hospital during a pandemic or thought short stature was not an urgent issue. Since the rate of GHD among referred children was similar in the 2 years (30% in 2019, 35% in 2020) and coherent with previous data [1, 14] we probably missed 8 GHD diagnoses in 2020. Although these children might have been referred and eventually treated at a later stage, we know that the efficacy of treatment is increased if started at a younger age [15]. Moreover, approximately 35% of the patients with GHD have an organic etiology, and a delay in such a diagnosis can be life-threatening [16].

On the other side, our study found a clinically meaningful increase in CPP diagnoses in girls (+16%) during 2020 compared to the same period in 2019. A “breast bud” appearance in a girl before the age of 8 years is always troublesome and easier to detect by families, even without comparisons with peers. Moreover, parents working from home might have increased the time spent with their children, detecting early pubertal changes more quickly. On the other hand, there was a decrease of 75% in CPP diagnosis in males. This reduction can be determined by the subtle finding of testicular enlargement (the earliest evidence of puberty

| Suspected diagnosis | 2019                  | 2020                  |
|---------------------|-----------------------|-----------------------|
|                     | Normal | Pathological | Total | Normal | Pathological | Total |
| CPP                 |         |             |       |         |             |       |
| Females             | 24 (50%) | 24 (50%) | 48 | 26 (49%) | 28 (51%) | 54 |
| Males               | 2       | 8           | 10  | 7       | 2           | 9    |
| HH                  | 13 (73%) | 5 (27%) | 18  | 26 (96%) | 1 (4%) | 27 |
| **Total**           | 66      |             | 81  |         |             |       |

CPP: Central Precocious Puberty, HH: Hypogonadotropic Hypogonadism
in males) that patients and parents often go unnoticed and can be missed if well-child visits from family pediatricians are missed.

An increase in the incidence of CPP had already been reported years before the advent of the COVID-19 pandemic in several countries, including France (Gaspari L, et al. [17]), Korea (Kim SH et al., [18]) and Denmark (Sømod ME, et al. [19]), but not Italy where both referrals for CPP [1] and new diagnosis of CPP (Stagi [20]) were stable during the previous 5 years.

Our findings of an increase of CPP during COVID-19 lockdown are in accordance with other two Italian reports: the first study found an increased incidence of newly diagnosed CPP in females with a faster rate of pubertal progression during COVID-19 pandemics compared to the same period, each year, from 2015 to 2019 [20]; similarly, in the second study, a rise in referrals for suspected precocious puberty was recorded in 2020 (+108% consultations compared to 2019) [21]. Since the hypothesis of a direct effect of Sars-CoV2 as a trigger of puberty remains unlikely, these results seem to suggest a possible role of environmental factors on the early onset of puberty during COVID-19 pandemics [22].

Precocious pubertal timing is crucial, resulting in a child sexually mature at an emotionally and socially inappropriate age, thus leading to risk-taking behaviors as sexual relations and substance use [23]. Genetics plays a significant role in CPP; however, environmental factors as obesity and adverse childhood experiences may influence pubertal development [24, 25]. Moreover, epidemiological studies in humans demonstrated that exposures to endocrine-disrupting compounds have pronounced effects on pubertal timing increasing an early onset of puberty [26]. Since COVID-19 outbreak limitations forced children to home-schooling and sedentary lifestyle, a cross-sectional study found a change in dietary habits, with increased consumption of hypercaloric foods as pizza, bread, sweets, and more snacking, thus leading to overweight [27]. Considering these observations, we hypothesized a possible association of increased overweight secondary to COVID-19 restrictions and early puberty. Interestingly, we found no increase in BMI SDS between early pubertal girls observed in 2020. Our results align with an Italian report on referrals for precocious puberty in 2020, where no significant differences in anthropometric parameters were found compared to 2019 [21]. COVID-19 restrictions exposed children to e-learning and increased the use of screens. Stagi et al. found a more than doubled increase in time spent using electronic devices in children during the lockdown, hypothesizing its possible role in triggering puberty’s early onset and tempo [20].

A potential limitation of this study is based on data collected retrospectively from a single center; therefore, results may be related to the local population and did not allow further analysis on other contributing factors. On the other hand, to our knowledge, this is the first study that has simultaneously analyzed the features of pediatric endocrine stimulation tests as a whole during COVID-19 pandemics. Another limitation is the comparison between 2 years (2019 and 2020) only, while it could have been interesting to analyze data from the previous years, as well as it could be interesting to evaluate data in the following years to evaluate if the founded changes were part of a trend from the previous years or were limited to the lockdown restrictions or due to the change in everyday life during pandemic years.

Conclusion
This study found a significant reduction of tests investigating GHD during COVID-19 pandemics, suggesting that a considerable number of children with GHD may have missed the opportunity of a timely diagnosis. It also showed a clinically meaningful increase in cases of CPP in girls. These results suggest the need for families and pediatricians to monitor children’s growth during isolation and enlighten new perspectives towards conditions associated with lockdown restrictions as increased screen time, social isolation, and children’s anxiety as possible triggers of CPP.

Since COVID-19 continues to represent a major global health threat challenging the accessibility to healthcare services, clinicians and the public health system should be aware that reduced access to health care is detrimental to both diagnosis and treatment of endocrine conditions.

Abbreviations
AGHD: Adult Growth Hormone Deficiency; AIFA: Italian Medicines Agency; ATT: Arginine Tolerance Test; ATT+GHRHT: Arginine Tolerance Test + Growth Hormone Releasing Hormone Test; BMI SDS: Body Mass Index Standard Deviation Score; CAI: Central Adrenal Insufficiency; CH: Central Hypothyroidism; CPP: Central Precocious Puberty; CRHT: Corticotropin-Releasing Hormone Test; CTT: Clonidine Tolerance Test; GHD: Growth Hormone Deficiency; HH: Hypogonadotropic Hypogonadism; IQR: InterQuartile Ranges; ITT: Insulin Tolerance Test; LDST: Low-Dose Synacthen Test; LHRHT: Luteinizing Hormone-Releasing Hormone Test; NC-CAH: Non-Classical Congenital Adrenal Hyperplasia; OG: OverGrowth; OGTT: Oral Glucose Tolerance Test; SDST: Standard-Dose Synacthen Test; TRHT: Thyrotropin Releasing Hormone.

Acknowledgements
Not applicable.

Authors’ contributions
MP, BB and AP conceptualized and designed the study, drafted the initial manuscript, designed the data collection instruments, collected data, and reviewed and revised the manuscript. MG carried out the statistical analysis and reviewed and revised the manuscript. VV, GV, and NG performed the stimulation tests and reviewed and revised the manuscript. MCP, EF, and EB conceptualized and designed the study and critically reviewed the manuscript.
for important intellectual content. GT conceptualized and designed the study, carried out the statistical analysis, drafted the initial manuscript, coordinated and supervised the data collection, and reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding
No funding was secured for this study.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author, GT, upon reasonable request.

Declarations

Ethics approval and consent to participate
Ethical Committee approval was not requested since General Authorization to Process Personal Data for Scientific Research Purposes (Authorization no. 9/2014) declared that retrospective archive studies that use ID codes, preventing the data from being traced back directly to the data subject, do not need ethics approval. Parents signed informed consent at the first visit, in which they agreed that clinical data may be used for clinical research purposes, epidemiology, the study of pathologies and training, to improve knowledge, care, and prevention.*

Consent for publication
Not needed.

Competing interests
The authors have no conflicts of interest to report and no financial interests to disclose.

Author details
1 University of Trieste, Trieste, Italy. 2 Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, Via dell'Istria, 65/1, 34137 Trieste, Italy.

Received: 24 July 2021 Accepted: 8 March 2022
Published online: 28 March 2022

References
1. Bellotto E, Monasta L, Pellegrin MC, et al. Pattern and features of pediatric endocrinology referrals: a retrospective study in a single tertiary center in Italy. Front Pediatr. 2020;8:580588.
2. Penco A, Bossini B, Giangreco M, et al. Should pediatric endocrinologists consider more carefully when to perform a stimulation test? Front Endocrinol (Lausanne). 2021;12:660692.
3. Lazzerini M, Barbi E, Apicella A, et al. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020;4(5):e10–1.
4. Ciocchini B, Tonioni F, Marciano C, et al. Reluctance to seek pediatric care during the COVID-19 pandemic and the risks of delayed diagnosis. Ital J Pediatr. 2020;46:87.
5. Wise J. Covid-19: delays in attending emergency departments may have contributed to deaths of nine children. BMJ. 2020;369:m2624.
6. Snopiri O, Rosenberg Danziger C, Krause I, Kravarusic D, Yulevich A, Balla U, et al. Delayed diagnosis of paediatric appendicitis during the COVID-19 pandemic. Acta Paediatr. 2020;109:1672–6.
7. Cozzi G, Zanchi C, Giangreco M, Rabach I, Calligaris L, Giorgi R, et al. The impact of the COVID-19 lockdown in Italy on a paediatric emergency setting. Acta Paediatr. 2020;109(10):2157–9.
8. Rabbone I, Schiaffini R, Cherubini V, Maffei C, Scarazzuza A. Diabetes study Group of the Italian Society for pediatric endocrinology and diabetes. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care. 2020;43(11):2870–2.
9. Ramos-Lacuey B, Herranz Aguilar M, Calderón Gallego C, et al. ECEN-2020 study: the effect of COVID-19 on admissions for non-COVID-19 diseases. World J Pediatr. 2021;17(1):85–91.
10. Moynhan R, Sanders S, Michaleff ZA, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343.
11. Raucci U, Musolino AA, Di Lallo D, et al. Impact of the COVID-19 pandemic on the emergency department of a tertiary children’s hospital. Ital J Pediatr. 2021;47:21.
12. The Italian Data Protection Authority. Available at: https://www.garan teprivacy.it/web/guest/home/docweb/-/docweb-display/docweb/3786078 (Accessed July 2021). Authorisation no. 9/2014 - General Authorisation to Process Personal Data for Scientific Research Purposes.
13. Italy. Determinazione dell’Agenzia Italiana del Farmaco 19 giugno 2014. Modifica alla Nota AIFA 39. Gazzetta Ufficiale. Serie Generale n. 154 del 5 luglio 2014.
14. Savage MO, Backeljauw PF, Calzada R, et al. Early detection, referral, investigation, and diagnosis of children with growth disorders. Horm Res Pediatr. 2016;85:325–32.
15. Polak M, Blair J, Kotnik P, et al. Early growth hormone treatment start in childhood growth hormone deficiency improves near-adult height: analysis from NordiNet® international outcome study. Eur J Endocrinol. 2017;177:421–9.
16. Thomas M, Massa G, Craen M, et al. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol. 2004;151(1):67–72.
17. Gaspari L, Morcrette E, Jeandel C, et al. Dramatic rise in the prevalence of precocious puberty in girls over the past 20 years in the south of France. ESPE Abstracts. 2014;82 P-D-2-1:539.
18. Kim SH, Huh K, Won S, Lee KW, Park MJ. A significant increase in the incidence of central precocious puberty among Korean girls from 2004 to 2010. PLoS One. 2015;10(11):e0141844.
19. Sammod ME, Vestergaard ET, Kristensen K, Birsbeek-NH. Increasing incidence of premature thelarche in the central region of Denmark - challenges in differentiating girls less than 7 years of age with premature thelarche from girls with precocious puberty in real-life practice. Int J Pediatr Endocrinol. 2016;2016:4.
20. Stagi S, De Masi S, Bencini E, Losi S, Paci S, Parpagnoi M, et al. Increased incidence of precocious and accelerated puberty in females during and after the Italian lockdown for the coronavirus 2019 (COVID-19) pandemic. Ital J Pediatr. 2020;46(1):165.
21. Verzani M, Bizzarri C, Chierna L, et al. Impact of COVID-19 pandemic lockdown on early onset of puberty: experience of an Italian tertiary center. Ital J Pediatr. 2021;47(1):52.
22. Street ME, Santori C, Castellani C, Righi B. Precocious puberty and Covid-19 into perspective: potential increased frequency, possible causes, and a potential emergency to be addressed. Front Pediatr. 2021;9:734899.
23. Willemens Rrt, Elleri D, Williams RM, Ong KK, Dunger DB. Pros and cons of GnRHa treatment for early puberty in girls. Nat Rev Endocrinol. 2014;10(6):352–63.
24. Reinehr T, Roth CL. Is there a causal relationship between obesity and puberty? Lancet Child Adolesc Health. 2019;3(1):44–54.
25. Zhang L, Zhang D, Sun Y. Adverse childhood experiences and early thelarche from girls with precocious puberty in real-life practice. Int J Pediatr Endocrinol. 2016;2016:4.
26. Street ME, Angelini S, Bernasconi S, et al. Current knowledge on endocrine disrupting chemicals (EDCs) from animal biology to humans, from pregnancy to adulthood: highlights from a national Italian meeting. Int J Mol Sci. 2018;19:1647-90.
27. Sidor A, Rzymski P. Dietary choices and habits during COVID-19 lockdown: experience from Poland. Nutrients. 2020;12(6):165.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.